Australia markets closed

    +21.50 (+0.28%)
  • ASX 200

    +25.50 (+0.34%)

    -0.0007 (-0.10%)
  • OIL

    -1.63 (-2.01%)
  • GOLD

    -2.40 (-0.12%)

    +197.45 (+0.62%)
  • CMC Crypto 200

    +9.65 (+1.87%)

    +0.0009 (+0.14%)

    -0.0026 (-0.24%)
  • NZX 50

    +12.59 (+0.10%)

    +115.12 (+0.96%)
  • FTSE

    +4.04 (+0.05%)
  • Dow Jones

    +28.67 (+0.08%)
  • DAX

    +17.18 (+0.11%)
  • Hang Seng

    +122.12 (+0.54%)
  • NIKKEI 225

    +19.81 (+0.07%)

Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

Roivant Sciences ROIV announced the formation of a new Vant company with Pfizer PFE to advance the development of PF-06480605, a TL1A-directed antibody originally developed by Pfizer, for treating inflammatory and fibrotic diseases. TL1A is a cytokine believed to play a key role in inflammation and fibrosis.

PF-06480605, now RVT-3101, is being developed in a phase IIb study for ulcerative colitis (UC), data from which is expected in the first half of 2023. The new Vant or Roivant subsidiary will take care of funding the global development of RVT-3101 in UC and additional inflammatory and fibrotic diseases. The Vant company holds commercial rights to the candidate in the United States and Japan. Pfizer has a 25% equity stake in the Vant company as well as commercial rights outside of the United States and Japan. Roivant Sciences holds the remaining stake in the company.

Roivant Sciences believes RVT-3101 has the potential to transform the inflammatory bowel diseases area as it can be the first approved biomarker-selected precision medicine for these chronic inflammatory diseases, which include UC and Crohn’s disease.

Roivant Sciences’ shares were up 8.2% on Thursday after it announced the deal with the pharma giant. In the year so far, the stock price of Roivant Sciences has plunged 42.4% compared with the industry’s decline of 18.2%.


Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research


The Vant company also has an exclusive option to collaborate with Pfizer on another next-generation TL1A-directed antibody, which is in early-stage development. Before the candidate enters phase II development, expected in 2025, the Vant can choose to enter into a global development agreement for the drug with 50/50 cost sharing as well as co-commercialization rights.

Zacks Rank

Roivant Sciences currently has a Zacks Rank #3 (Hold).

Some better-ranked large drugmakers are Vertex Pharmaceuticals VRTX and Gilead Sciences GILD, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Vertex Pharmaceuticals’ stock has risen 46.1% this year so far. Estimates for Vertex’s 2022 earnings have gone up from $14.21 to $14.61 per share, while that for 2023 have increased from $15.09 to $15.60 per share over the past 60 days.

Vertex has a four-quarter earnings surprise of 3.16%, on average.

Estimates for Gilead’s 2022 earnings per share have increased from $6.61 per share to $7.09 per share, while that for 2023 have increased from $6.30 per share to $6.79 per share in the past 30 days. Gilead’s stock is up 21.1% in the year-to-date period.

Gilead beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 0.36%, on average.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

Roivant Sciences Ltd. (ROIV) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research